LYFCX Mutual Fund (AlphaCentric Life Sciences and Healthcare Fund Class C) is managed by Alpha Centric Fund with $1.9M in net assets. LYFCX expense ratio is 2.46%, holding 65 positions across sectors including Health Care, Unknown, Financials. Inception date: 2019-11-29.

LYFCX performance shows a YTD return of 3.83%. The 1-year return is 24.00% and the 5-year return is 3.37%. LYFCX dividend yield stands at 0.72%, paid annually.

LYFCX top holdings include Gilead Sciences Inc (7.9%), Nvaesrtex Pharmaceuticals Inc (6.0%), Developed Markets Astrazeneca Plc Sponsored Adr (5.3%), Insmed Inc Sedol 2614487 (4.1%), Ionis Pharmaceuticals Inc (4.0%). View all LYFCX holdings, sector breakdown, or dividend history.

LYFCX can be compared against other funds using the overlap calculator or side-by-side comparison tool. LYFCX alternatives are available via the screener, along with tax-loss harvesting opportunities.